SEHK:1177Pharmaceuticals
Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Sanofi Rovadicitinib Licensing Agreement
Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after signing an exclusive global license agreement with Sanofi for its JAK/ROCK inhibitor rovadicitinib, tied to upfront, milestone and royalty payments.
See our latest analysis for Sino Biopharmaceutical.
The Sanofi licensing news arrives at a time when Sino Biopharmaceutical’s shares trade at HK$6.13, with a 1 day share price return of 3.72% and a year to date share price return decline of 3.62%. However, a 1 year total...